JPWO2021007278A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021007278A5 JPWO2021007278A5 JP2022500900A JP2022500900A JPWO2021007278A5 JP WO2021007278 A5 JPWO2021007278 A5 JP WO2021007278A5 JP 2022500900 A JP2022500900 A JP 2022500900A JP 2022500900 A JP2022500900 A JP 2022500900A JP WO2021007278 A5 JPWO2021007278 A5 JP WO2021007278A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- lipids
- mrna
- independently
- lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000002632 lipids Chemical class 0.000 claims description 101
- 239000002105 nanoparticle Substances 0.000 claims description 51
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 48
- 239000000203 mixture Substances 0.000 claims description 47
- 238000000034 method Methods 0.000 claims description 46
- 108020004999 messenger RNA Proteins 0.000 claims description 40
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 36
- 235000012000 cholesterol Nutrition 0.000 claims description 24
- 125000002091 cationic group Chemical group 0.000 claims description 23
- 229920001184 polypeptide Polymers 0.000 claims description 20
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 20
- 102000004169 proteins and genes Human genes 0.000 claims description 19
- 108090000623 proteins and genes Proteins 0.000 claims description 19
- 125000001931 aliphatic group Chemical group 0.000 claims description 14
- 230000001225 therapeutic effect Effects 0.000 claims description 14
- MWRBNPKJOOWZPW-GPADLTIESA-N 1,2-di-[(9E)-octadecenoyl]-sn-glycero-3-phosphoethanolamine Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C\CCCCCCCC MWRBNPKJOOWZPW-GPADLTIESA-N 0.000 claims description 13
- 229930182558 Sterol Natural products 0.000 claims description 12
- 150000003432 sterols Chemical class 0.000 claims description 12
- 235000003702 sterols Nutrition 0.000 claims description 12
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 125000003827 glycol group Chemical group 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- SSCDRSKJTAQNNB-DWEQTYCFSA-N 1,2-di-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphoethanolamine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC SSCDRSKJTAQNNB-DWEQTYCFSA-N 0.000 claims description 5
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 4
- 150000008064 anhydrides Chemical group 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 125000000732 arylene group Chemical group 0.000 claims description 4
- 238000009295 crossflow filtration Methods 0.000 claims description 4
- 230000002950 deficient Effects 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 150000007970 thio esters Chemical class 0.000 claims description 4
- 238000005538 encapsulation Methods 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- VBZSMBBOZFITID-FRWASNMLSA-N (2-aminoethoxy)[(2r)-2,3-bis[(13z)-docos-13-enoyloxy]propoxy]phosphinic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCC\C=C/CCCCCCCC VBZSMBBOZFITID-FRWASNMLSA-N 0.000 claims description 2
- ZISVTYVLWSZJAL-UHFFFAOYSA-N 3,6-bis[4-[bis(2-hydroxydodecyl)amino]butyl]piperazine-2,5-dione Chemical compound CCCCCCCCCCC(O)CN(CC(O)CCCCCCCCCC)CCCCC1NC(=O)C(CCCCN(CC(O)CCCCCCCCCC)CC(O)CCCCCCCCCC)NC1=O ZISVTYVLWSZJAL-UHFFFAOYSA-N 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- -1 imidazole cholesterol ester Chemical class 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- JZNWSCPGTDBMEW-YFKPBYRVSA-N sn-glycero-3-phosphoethanolamine Chemical compound NCCO[P@@](O)(=O)OC[C@@H](O)CO JZNWSCPGTDBMEW-YFKPBYRVSA-N 0.000 claims description 2
- FHQVHHIBKUMWTI-OTMQOFQLSA-N {1-hexadecanoyl-2-[(Z)-octadec-9-enoyl]-sn-glycero-3-phospho}ethanolamine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC FHQVHHIBKUMWTI-OTMQOFQLSA-N 0.000 claims 1
- GFHUWBRIPPDHNR-CGACMRCQSA-N 2-aminoethyl [(2r)-2,3-bis[(z)-docos-13-enoxy]propyl] hydrogen phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCCOC[C@H](COP(O)(=O)OCCN)OCCCCCCCCCCCC\C=C/CCCCCCCC GFHUWBRIPPDHNR-CGACMRCQSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024194073A JP2025024002A (ja) | 2019-07-08 | 2024-11-06 | 改善されたｍＲＮＡ装填脂質ナノ粒子、およびそれを作製するプロセス |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962871513P | 2019-07-08 | 2019-07-08 | |
| US62/871,513 | 2019-07-08 | ||
| PCT/US2020/041122 WO2021007278A1 (en) | 2019-07-08 | 2020-07-08 | Improved mrna-loaded lipid nanoparticles and processes of making the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024194073A Division JP2025024002A (ja) | 2019-07-08 | 2024-11-06 | 改善されたｍＲＮＡ装填脂質ナノ粒子、およびそれを作製するプロセス |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022541740A JP2022541740A (ja) | 2022-09-27 |
| JP2022541740A5 JP2022541740A5 (https=) | 2023-06-30 |
| JPWO2021007278A5 true JPWO2021007278A5 (https=) | 2023-06-30 |
| JP7586886B2 JP7586886B2 (ja) | 2024-11-19 |
Family
ID=71784731
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022500900A Active JP7586886B2 (ja) | 2019-07-08 | 2020-07-08 | 改善されたｍＲＮＡ装填脂質ナノ粒子、およびそれを作製するプロセス |
| JP2024194073A Pending JP2025024002A (ja) | 2019-07-08 | 2024-11-06 | 改善されたｍＲＮＡ装填脂質ナノ粒子、およびそれを作製するプロセス |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024194073A Pending JP2025024002A (ja) | 2019-07-08 | 2024-11-06 | 改善されたｍＲＮＡ装填脂質ナノ粒子、およびそれを作製するプロセス |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230181483A1 (https=) |
| EP (2) | EP4467653B1 (https=) |
| JP (2) | JP7586886B2 (https=) |
| KR (1) | KR20220078557A (https=) |
| CN (2) | CN114390921B (https=) |
| AU (1) | AU2020311364B2 (https=) |
| CA (1) | CA3146369A1 (https=) |
| ES (1) | ES2992127T3 (https=) |
| WO (1) | WO2021007278A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019046809A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | METHODS OF MANUFACTURING LIPID NANOPARTICLES |
| US20230181483A1 (en) * | 2019-07-08 | 2023-06-15 | Translate Bio, Inc. | Improved mrna-loaded lipid nanoparticles and processes of making the same |
| US12053551B2 (en) | 2019-12-20 | 2024-08-06 | Translate Bio, Inc. | Process of preparing mRNA-loaded lipid nanoparticles |
| JP2024527940A (ja) * | 2021-07-26 | 2024-07-26 | モデルナティエックス インコーポレイテッド | ペイロード分子を気道上皮に送達するための脂質ナノ粒子組成物を調製するプロセス |
| MX2024002726A (es) | 2021-09-03 | 2024-03-20 | CureVac SE | Nuevas nanoparticulas lipidicas para la administracion de acidos nucleicos. |
| KR20230053998A (ko) | 2021-10-15 | 2023-04-24 | (주)지노믹트리 | mRNA 발현을 위한 유전자 구조체 |
| WO2023073228A1 (en) | 2021-10-29 | 2023-05-04 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
| US20250099614A1 (en) | 2022-01-28 | 2025-03-27 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
| WO2023227608A1 (en) | 2022-05-25 | 2023-11-30 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide |
| US20260069713A1 (en) | 2022-08-29 | 2026-03-12 | Vivasor, Inc. | Lipid-Coated Nanoparticles |
| WO2024089638A1 (en) | 2022-10-28 | 2024-05-02 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine |
| KR20250153298A (ko) | 2023-03-08 | 2025-10-24 | 큐어백 에스이 | 핵산 전달을 위한 신규의 지질 나노입자 제형 |
| WO2024230934A1 (en) | 2023-05-11 | 2024-11-14 | CureVac SE | Therapeutic nucleic acid for the treatment of ophthalmic diseases |
| EP4722368A1 (en) | 2023-05-26 | 2026-04-08 | Samsung Biologics Co., Ltd. | Novel nucleic acid construct comprising poly(a) tail having secondary or tertiary structure and uses thereof |
| KR20250018367A (ko) | 2023-07-28 | 2025-02-05 | 한국과학기술원 | 히스톤 코드 리더 도메인을 포함하는 폴리펩티드 및 이의 용도 |
| TW202543583A (zh) * | 2024-03-01 | 2025-11-16 | 加拿大商阿奎特斯醫療公司 | 用於將治療劑包覆於脂質奈米顆粒中之材料及方法 |
| CN121265551A (zh) * | 2024-07-02 | 2026-01-06 | 苏州星核迪赛生物技术有限公司 | 一种靶向肝实质细胞的核酸递送载体及其应用 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1580968A (en) | 1923-01-26 | 1926-04-13 | Brazza Ascanio Di | Firearm with screwed barrel detachable by hand or permanently fixed |
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US4500707A (en) | 1980-02-29 | 1985-02-19 | University Patents, Inc. | Nucleosides useful in the preparation of polynucleotides |
| US5132418A (en) | 1980-02-29 | 1992-07-21 | University Patents, Inc. | Process for preparing polynucleotides |
| US4973679A (en) | 1981-03-27 | 1990-11-27 | University Patents, Inc. | Process for oligonucleo tide synthesis using phosphormidite intermediates |
| US4668777A (en) | 1981-03-27 | 1987-05-26 | University Patents, Inc. | Phosphoramidite nucleoside compounds |
| US4415732A (en) | 1981-03-27 | 1983-11-15 | University Patents, Inc. | Phosphoramidite compounds and processes |
| US4401796A (en) | 1981-04-30 | 1983-08-30 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
| US4373071A (en) | 1981-04-30 | 1983-02-08 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US5153319A (en) | 1986-03-31 | 1992-10-06 | University Patents, Inc. | Process for preparing polynucleotides |
| US5262530A (en) | 1988-12-21 | 1993-11-16 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
| US5047524A (en) | 1988-12-21 | 1991-09-10 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
| FR2645866B1 (fr) | 1989-04-17 | 1991-07-05 | Centre Nat Rech Scient | Nouvelles lipopolyamines, leur preparation et leur emploi |
| US5334761A (en) | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US5700642A (en) | 1995-05-22 | 1997-12-23 | Sri International | Oligonucleotide sizing using immobilized cleavable primers |
| US5744335A (en) | 1995-09-19 | 1998-04-28 | Mirus Corporation | Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein |
| US7799565B2 (en) | 2004-06-07 | 2010-09-21 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering RNA |
| CN104119242B (zh) | 2008-10-09 | 2017-07-07 | 泰米拉制药公司 | 改善的氨基脂质和递送核酸的方法 |
| ES2646630T3 (es) | 2008-11-07 | 2017-12-14 | Massachusetts Institute Of Technology | Lipidoides aminoalcohólicos y usos de los mismos |
| MX342785B (es) | 2009-06-10 | 2016-10-12 | Alnylam Pharmaceuticals Inc | Formulacion mejorada de lipido. |
| HUE042177T2 (hu) | 2009-12-01 | 2019-06-28 | Translate Bio Inc | Szteroidszármazék mRNS szállítására humán genetikai betegségekben |
| EP3354644A1 (en) | 2011-06-08 | 2018-08-01 | Translate Bio, Inc. | Cleavable lipids |
| KR102451116B1 (ko) | 2011-10-27 | 2022-10-06 | 메사추세츠 인스티튜트 오브 테크놀로지 | 약물 캡슐화 마이크로스피어를 형성할 수 있는, ｎ-말단 상에 관능화된 아미노산 유도체 |
| ES2762873T3 (es) | 2012-03-29 | 2020-05-26 | Translate Bio Inc | Lípidos catiónicos ionizables |
| ES2895651T3 (es) | 2013-12-19 | 2022-02-22 | Novartis Ag | Lípidos y composiciones lipídicas para la administración de agentes activos |
| JP6557722B2 (ja) | 2014-05-30 | 2019-08-07 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | 核酸の送達のための生分解性脂質 |
| SMT202200502T1 (it) | 2014-06-25 | 2023-01-13 | Acuitas Therapeutics Inc | Nuovi lipidi e formulazioni di nanoparticelle lipidiche per l'erogazione di acidi nucleici |
| US9840479B2 (en) | 2014-07-02 | 2017-12-12 | Massachusetts Institute Of Technology | Polyamine-fatty acid derived lipidoids and uses thereof |
| BR112016030852A2 (pt) | 2014-07-02 | 2018-01-16 | Shire Human Genetic Therapies | encapsulação de rna mensageiro |
| US20180000953A1 (en) | 2015-01-21 | 2018-01-04 | Moderna Therapeutics, Inc. | Lipid nanoparticle compositions |
| WO2016118725A1 (en) | 2015-01-23 | 2016-07-28 | Moderna Therapeutics, Inc. | Lipid nanoparticle compositions |
| ES2949540T3 (es) * | 2015-06-19 | 2023-09-29 | Massachusetts Inst Technology | 2,5-piperazinadionas sustituidas con alquenilo y su uso en composiciones para suministrar un agente a un sujeto o una célula |
| LT3313829T (lt) | 2015-06-29 | 2024-08-12 | Acuitas Therapeutics Inc. | Lipidai ir lipidų nanodalelių sudėtys, skirtos nukleorūgščių tiekimui |
| EP4286012A3 (en) | 2015-09-17 | 2024-05-29 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| IL307179A (en) | 2015-10-28 | 2023-11-01 | Acuitas Therapeutics Inc | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| EP3397613A1 (en) | 2015-12-30 | 2018-11-07 | Acuitas Therapeutics Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| TWI773666B (zh) | 2016-03-30 | 2022-08-11 | 美商英特利亞醫療公司 | Crispr/cas 組分之脂質奈米粒子調配物 |
| EP3315125A1 (en) * | 2016-10-31 | 2018-05-02 | Silence Therapeutics (London) Ltd | Lipid nanoparticle formulation |
| WO2018089801A1 (en) | 2016-11-10 | 2018-05-17 | Translate Bio, Inc. | Improved process of preparing mrna-loaded lipid nanoparticles |
| MX2019005470A (es) | 2016-11-10 | 2019-11-21 | Translate Bio Inc | Formulación de nanopartículas lipídicas basadas en ice mejorada para el suministro de arnm. |
| MA47824A (fr) | 2017-03-07 | 2020-01-15 | Translate Bio Inc | Administration polyanionique d'acides nucléiques |
| MX2021005482A (es) * | 2018-11-09 | 2021-09-08 | Translate Bio Inc | Lípidos de 2,5-dioxopiperazina con porciones éster, tioéster, disulfuro y anhidrido intercaladas. |
| WO2020097511A2 (en) * | 2018-11-09 | 2020-05-14 | Translate Bio, Inc. | Messenger rna therapy for treatment of ocular diseases |
| US20230181483A1 (en) * | 2019-07-08 | 2023-06-15 | Translate Bio, Inc. | Improved mrna-loaded lipid nanoparticles and processes of making the same |
-
2020
- 2020-07-08 US US17/625,507 patent/US20230181483A1/en active Pending
- 2020-07-08 EP EP24189330.4A patent/EP4467653B1/en active Active
- 2020-07-08 CN CN202080062330.7A patent/CN114390921B/zh active Active
- 2020-07-08 CA CA3146369A patent/CA3146369A1/en active Pending
- 2020-07-08 WO PCT/US2020/041122 patent/WO2021007278A1/en not_active Ceased
- 2020-07-08 JP JP2022500900A patent/JP7586886B2/ja active Active
- 2020-07-08 ES ES20745451T patent/ES2992127T3/es active Active
- 2020-07-08 AU AU2020311364A patent/AU2020311364B2/en active Active
- 2020-07-08 EP EP20745451.3A patent/EP3996683B1/en active Active
- 2020-07-08 CN CN202411475913.9A patent/CN119454644A/zh active Pending
- 2020-07-08 KR KR1020227004274A patent/KR20220078557A/ko active Pending
-
2024
- 2024-11-06 JP JP2024194073A patent/JP2025024002A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025024002A5 (https=) | ||
| JPWO2021007278A5 (https=) | ||
| US11406597B2 (en) | Fusogenic liposome-coated porous silicon nanoparticles | |
| Moghimi et al. | Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties | |
| Allen et al. | Antibody-mediated targeting of long-circulating (StealthR) liposomes | |
| KR101617790B1 (ko) | 치료, 진단과 실험적 혼합물들의 운반을 위한 공학적으로 가변된 나노입자 및 치료용 관련 조성물 | |
| JP6689378B2 (ja) | 巨大分子の経口送達のための細胞浸透性ペプチド及びテトラエーテル脂質を含むリポソーム | |
| US20090110739A1 (en) | Targeted cancer chemotherapy using synthetic nanoparticles | |
| Jølck et al. | Engineering liposomes and nanoparticles for biological targeting | |
| CN101170995A (zh) | 新颖的脂质体组合物 | |
| WO1992019752A1 (fr) | Vecteur de delivrance d'arn | |
| US9173839B2 (en) | Anionic lipids and lipid nano-structures and methods of producing and using same | |
| Paillard et al. | Positively-charged, porous, polysaccharide nanoparticles loaded with anionic molecules behave as ‘stealth’cationic nanocarriers | |
| WO2009044406A4 (en) | Stearically stabilized unilamilar vesicles, process for preparation thereof and use thereof | |
| WO2004098537A2 (en) | Activation agents on the surface of encapsulation vesicles | |
| WO1991004019A1 (en) | Therapeutic peptides and proteins | |
| Li et al. | Optimal delivery strategies for nanoparticle-mediated mRNA delivery | |
| JP2021042193A5 (https=) | ||
| Sonju et al. | Liposome nanocarriers for peptide drug delivery | |
| EP1832280A1 (en) | Liposome allowing the discharge of substance entrapped therein from endosome | |
| CN1774281B (zh) | 包含蛋白质和/或多肽以及胶体颗粒的药物组合物 | |
| JP2023533797A (ja) | 脂質複合体を含む経口医薬組成物 | |
| CN113350512B (zh) | PEG2,n-脂质衍生物修饰的纳米载体、制备方法及应用 | |
| JPH07291853A (ja) | リポソームおよび薬物運搬体 | |
| JP7523159B2 (ja) | ポリペプチドアルブミンナノ粒子、およびその調製方法と使用 |